Bharat Immunologicals & Biologicals Corporation Ltd Profit & Loss Annual

BSE: 524663 | NSE: - | ISIN: INE994B01014 | Sector: Biotechnology & Drugs

16.02 +0.09 (0.56%)Updated : 18 Aug 2026

Research on

Interim Data

Annual Data

Fiscal Period	2023	2022	2021	2020
Period End Date	Mar 23	Mar 22	Mar 21	Mar 20
Total Operating Expense	63.22	83.59	106.44	77.48
Net Income After Taxes	-17.06	-8.75	-18.11	-10.21
Income Availableto Com Incl Extra Ord	-17.06	-8.75	-18.11	-10.21
Costof Revenue Total	54.31	73.48	95.66	67.34
Other Net	2.80	0.61	1.25	0.49
Gross Profit	-9.70	4.91	-10.33	-0.50
Interest Inc( Exp) Net- Non- Op Total	-7.04	-5.10	-4.35	-4.05
Diluted Weighted Average Shares	4.32	4.32	4.32	4.32
Diluted Net Income	-17.06	-8.75	-18.11	-10.21
Provisionfor Income Taxes	-5.79	-0.93	-6.10	-3.99
Depreciation/ Amortization	0.15	0.21	0.24	0.24
period Type	-	-	-	-
Net Income Before Extra Items	-17.06	-8.75	-18.11	-10.21
Total Revenue	44.61	78.39	85.33	66.84
Operating Income	-18.61	-5.20	-21.11	-10.65
Net Income	-17.06	-8.75	-18.11	-10.21
period Length	12.00	12.00	12.00	12.00
Revenue	44.61	78.39	85.33	66.84
Income Availableto Com Excl Extra Ord	-17.06	-8.75	-18.11	-10.21
Other Operating Expenses Total	8.77	9.89	10.55	9.91
Net Income Before Taxes	-22.85	-9.69	-24.21	-14.20
Diluted Normalized EPS	-3.95	-2.03	-4.19	-2.36
Diluted EPS Excluding Extra Ord Items	-3.95	-2.03	-4.19	-2.36
Total Adjustmentsto Net Income	-	-	0.00	-